Clinical Trial

Body Composition in Metastatic Breast Cancer

Study Description

Pilot Study Assessing the Effect of Cyclin-dependent Kinase 4/6 Inhibitors on Body Composition in Patients With ER+/HER2- Metastatic Breast Cancer

The goal of this study is to evaluate changes in body composition among patients who are treated with cyclin-dependent kinase (CDK) 4/6 inhibitors (abemaciclib, ribociclib, or palbociclib).

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Diagnostic Test - CT scans

Patients will undergo CT or PETCT as part of their standard of care

Diagnostic Test - DEXA scan

Patients will undergo DEXA scan to measure body fat mass. This is part of proposed study.

Additional Information

Official Study Title

Pilot Study Assessing the Effect of Cyclin-dependent Kinase 4/6 Inhibitors on Body Composition in Patients With ER+/HER2- Metastatic Breast Cancer

Clinical Trial ID

NCT03697577

ParticipAid ID

bmZyOd